✦ LIBER ✦

Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient

✍ Scribed by E. Willenbacher; W. Willenbacher; E. Gunsilius

Book ID: 113100575
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 202 KB
Volume: 5
Category: Article
ISSN: 1865-5041
DOI: 10.1007/s12254-012-0345-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rapid response of plasmacytomas to lenal

Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma

✍ Toshihiro Fukushima; Takuji Nakamura; Haruka Iwao; Hisanori Umehara 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Primary therapy with single agent bortez

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial

✍ Dispenzieri, A; Jacobus, S; Vesole, D H; Callandar, N; Fonseca, R; Greipp, P R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 327 KB

Achievement of at Least Very Good Partia

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

✍ Harousseau, J.-L.; Avet-Loiseau, H.; Attal, M.; Charbonnel, C.; Garban, F.; Huli 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 236 KB